ConductScience.org, home

Trial · NCT07911280

A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy

NCT07911280, Phase 2, Recruiting, Samsung Medical Center

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy. Trials, record NCT07911280. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911280

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy
NCT number
NCT07911280
Status
Recruiting
Phases
Phase 2
Enrollment
20 participants, estimated
Lead sponsor
Samsung Medical Center
Conditions
Gastric Cancer
Interventions
Trastuzumab + Durvalumab + FLOT
First posted
2026-11-02
Last updated
2026-11-02

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryNumber of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0
From Cycle 1 Day 1 of neoadjuvant treatment through completion of postoperative adjuvant XELOX (6-8 cycles) Neoadjuvant Chemotherapy - Cycle length: 2 weeks (14 days) - Total duration: 4 cycles (8 weeks) Adjuvant Chemotherapy - Cycle length: 3 weeks (21D
Evaluation of safety of neoadjuvant FLOT + Trastuzumab + Durvalumab therapy
SecondaryPercentage of Participants Achieving R0 ResectionAt the time of definitive surgery (perioperative)
The percentage of participants achieving R0 resection following neoadjuvant FLOT plus trastuzumab and durvalumab therapy. R0 resection is defined as complete surgical removal of the tumor with microscopically negative resection margins, as determined by histopathological examination of surgical specimens.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07911280

GET https://conductscience.org/api/trials/v1/NCT07911280/registered